STOCKSCREENR

CAPR

NASDAQ

Capricor Therapeutics, Inc.

$33.58+1.12(+3.45%)Mkt Cap: $1.54B

Key Stats

Market Cap

$1.54B

P/E Ratio

-14.86

EPS

$-2.26

Dividend Yield

0.00%

52-Week Range

$4.30 — $40.37

Volume

747.03K

Avg Volume

1.25M

Beta

0.48

Price Alerts for CAPR

Get alerted when CAPR hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-14.86

Forward P/E

172.21

PEG Ratio

0.58

P/S (TTM)

0.00

P/B (TTM)

5.13

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-0.68%

ROA (TTM)

-0.30%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.07

Current Ratio

9.01

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.15%

EPS Growth (5Y)

+0.03%

Sales Growth (3Y)

+6.06%

Sales Growth (5Y)

+3.45%

EPS Est (This Year)

$0.20

EPS Est (Next Year)

$-0.24

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$6.51

Analyst Consensus

Price Target Range

$13.00$50.00$62.00
LowMedianHigh

Consensus Target: $47.75(42.2% upside)

Ownership

Institutional %

46.79%

Inst. Net Change

11.92M

Insider Net Shares (90d)

—

Outstanding Shares

45.72M

Float

37.80M

Free Float %

82.69%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2007-02-13

Employees

160

CEO

Linda Marbán

Index Membership

—

Website

https://www.capricor.com

Capricor Therapeutics, Inc. (CAPR) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $1.54B, a P/E ratio of -14.86, CAPR is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare CAPR against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

ARMP

Armata Pharmaceuticals, Inc.

$9.98

+4.50%

$365.60M

CBIO

Crescent Biopharma, Inc.

$22.37

+6.83%

$616.45M

NUVL

Nuvalent, Inc.

$100.28

+1.19%

$7.34B

ZBIO

Zenas BioPharma, Inc.

$19.32

+10.09%

$862.50M

GHRS

GH Research PLC

$20.53

+7.15%

$1.27B

Frequently Asked Questions

What is Capricor Therapeutics, Inc.'s P/E ratio?

Capricor Therapeutics, Inc. (CAPR) has a trailing twelve-month (TTM) P/E ratio of -14.86. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Capricor Therapeutics, Inc. pay a dividend?

No, Capricor Therapeutics, Inc. (CAPR) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Capricor Therapeutics, Inc.'s market cap?

Capricor Therapeutics, Inc. (CAPR) has a market capitalization of $1.54 billion, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.